Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240237 | 0.87 | MAPK11 (0.58) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4240574 | 0.84 | MAPK11 (0.58) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL29594918 | 0.84 | MAPK11 (0.58) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4243572 | 0.83 | MAPK13 (0.51) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4245919 | 0.83 | MAPK13 (0.55) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4239791 | 0.82 | MAPK13 (0.59) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4237364 | 0.82 | MAPK13 (0.53) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4241313 | 0.79 | MAPK11 (0.58) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4240677 | 0.79 | CYP2C9 (0.51) | MAPK13MAPK11CYP2C9FGFR1FGFR2 | |
| SCHEMBL4240662 | 0.78 | MAPK13 (0.56) | MAPK13MAPK11CYP2C9FGFR1FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | ASTELLAS PHARMA INC (JP) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042856-A1 | PYRIDAZINONE DERIVATIVES USED FOR THE TREATMENT OF PAIN | HRH2, OPRD1, HRH4 | MAPK13 1439/4885MAPK11 1195/4885CYP2C9 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.